Raphaël Ortiz Joins Telix as Chief Operating Officer, EMEA
Telix is pleased to announce that Raphaël Ortiz has joined the Company as Chief Operating Officer for Europe Middle East and Africa (EMEA).
First U.S. Patients Dosed in Phase III ZIRCON Trial of Renal Cancer Imaging Product
Telix Pharmaceuticals announces the first U.S. patients have been dosed in the Company’s Phase III ZIRCON trial.
Telix Pharmaceuticals Appoints Danielle Meyrick MD as CMO, Asia-Pacific
Telix is delighted to announce that Danielle Meyrick MD has joined its executive medical team in the role of Chief Medical Officer (CMO), Asia-Pacific.
ARTMS and Telix Pharmaceuticals Announce Successful Production of 68Ga PSMA-11 with Cyclotron Produced 68Ga from a Solid Target
ARTMS Inc. and Telix announce successful production of Telix’s prostate cancer imaging product using multi-Curie quantities of cyclotron-produced Gallium-68 via ARTMS’ proprietary Quantum Irradiation System (QIS®) solid target system.
Telix Pharmaceuticals Files New Drug Submission with Health Canada for Prostate Cancer Imaging Product
Telix has filed a New Drug Submission (NDS) with Health Canada for TLX591-CDx (Kit for the preparation of 68Ga-PSMA-11).
Telix Pharmaceuticals and Mauna Kea Technologies Launch Urologic Oncology Alliance
Telix Pharmaceuticals announces collaboration with Mauna Kea Technologies to develop advanced image-guided surgical technologies in the field of urologic oncology.
Telix and Kanazawa University Commence Japanese Clinical Study for Prostate Cancer Imaging
Telix announces its subsidiary, Telix Pharmaceuticals Japan KK, has entered a clinical study collaboration with Kanazawa University (Japan) for the conduct of a Phase I trial of its prostate cancer imaging product.
Telix Completes IP Agreement with the University of Southampton (UK) Granting Exclusive Access to TRALA Clinical Trial Data
Telix Pharmaceuticals Limited announces today that its wholly-owned subsidiary TheraPharm GmbH has completed an Intellectual Property (IP) agreement with the University of Southampton, UK
Telix Granted TGA Priority Review for Prostate Cancer Imaging
Telix has been granted Priority Review status for TLX591-CDx (68Ga-PSMA-11), a radiopharmaceutical for the imaging of prostate cancer using Positron Emission Tomography (PET).
Telix and DuChemBio Announce Korean Partnership for Advanced Prostate Cancer Imaging
Telix Pharmaceuticals announces it has entered into a licensing and partnership agreement with DuChemBio